Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Summary

This report contains a summary of the analyst consensus forecasts available in the Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available.

Scope

This 27-page report gives important, expert insight you won’t find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is required reading for -

• Investors that want to understand how COVID-19 has impacted Drug Revenues in the biopharmaceutical industry as well as identifying companies to invest in
• Companies that are interested in entering the COVID-19 disease space
• Large pharma companies with investment groups or BD teams looking for partnership opportunities in the COVID-19 disease space

Reasons to Buy

• Analysis of COVID-19 analyst consensus sales forecasts
• Overview of Pipeline portfolio of companies involved in COVID-19 disease space
• Detailed Analysis of how COVID-19 have affected analyst consensus sales forecasts for previously forecasted Drugs